Is GeoVax Labs, Inc. overvalued or undervalued?

As of 12 November 2024, the valuation grade for GeoVax Labs, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its financial health. The company appears to be overvalued given its troubling financial metrics, including a Price to Book Value of 2.15, an EV to Sales ratio of 1.71, and an EV to Capital Employed of 9.58, which suggest that investors are paying a premium for the company's assets despite its poor performance.
In comparison to its peers, GeoVax's valuation ratios are concerning; for instance, Catalyst Biosciences, Inc. is classified as expensive with a P/E ratio of 110.04, while Elutia, Inc. and 22nd Century Group, Inc. are both deemed risky with negative EV to EBITDA ratios of -5.54 and -0.62, respectively. Furthermore, GeoVax's stock has significantly underperformed against the S&P 500, with a year-to-date return of -73.22% compared to the index's 12.22%, reinforcing the notion that the company is currently overvalued.